Minnesota bill advances to launch psilocybin therapy pilot
Minnesota lawmakers are weighing House File 2906, a bill that would legalize supervised psilocybin 'magic mushroom' therapy in a tightly controlled, three‑year pilot program serving up to 1,000 patients statewide, including in the Twin Cities. The bill, authored by Rep. Andy Smith and now with bipartisan sponsors in both chambers, cleared its first hurdle Monday in the House Health Finance and Policy Committee. It would set up licensed cultivators and treatment facilities, require patients to be at least 21, undergo a health screening, obtain a certificate from a health‑care practitioner, and register with the state, paying an annual fee to remain in the program. The proposal follows recommendations from the state’s Psychedelic Medicine Task Force, which urged decriminalization based on emerging research that psilocybin can help treat depression, PTSD and addiction, and comes after a broader decriminalization bill stalled last year. For metro residents, the measure could eventually put a controversial but potentially powerful mental‑health treatment within reach at regulated clinics, while raising fresh questions about safety, oversight and who profits if Minnesota moves into the psychedelic‑medicine business.
📌 Key Facts
- House File 2906 would create a three‑year psilocybin therapy pilot program for up to 1,000 patients under state oversight.
- The bill specifies rules for mushroom cultivation, treatment facilities, and a public harm‑reduction education campaign.
- Eligibility would be limited to adults 21 and older who pass a health screening, obtain a practitioner certificate, and register annually with the state.
- The bill just received and passed its first hearing in the Minnesota House Health Finance and Policy Committee with bipartisan authorship.
- The state’s Psychedelic Medicine Task Force previously recommended decriminalizing psilocybin due to therapeutic potential for conditions like depression and PTSD.
📊 Relevant Data
In Minnesota, the prevalence of depression is higher among women compared to men, adults ages 18-44 compared to those age 65 and older, and multiracial adults have a prevalence three times higher than Asian adults.
Explore Depression in Minnesota | AHR — America's Health Rankings
From 2019 to 2023, Native Americans in Minnesota were at least 15 times more likely to die from opioid overdoses than White people.
Overlooked: Huge racial gaps emerge in Minnesota opioid deaths — Sahan Journal
Native American Minnesotans are dying from substance use disorders at over nine times the rate of White Minnesotans, and Black Minnesotans at over three times the rate.
In Minnesota, higher rates of PTSD include females (22.5%), 18-24-year-old age group (24.2%), and American Indian, non-Hispanic (35.2%).
2023 August 2021 Mental Health Data Profile - Olmsted County — Olmsted County
Psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability in major depressive disorder.
Single-Dose Psilocybin Treatment for Major Depressive Disorder — JAMA Network
Psilocybin-assisted psychotherapy showed significant reductions in alcohol use and high smoking cessation rates in studies on substance use disorders.
Efficacy and safety of psilocybin for the treatment of substance use ... — ScienceDirect
A systematic review assessed the efficacy of psilocybin in patients with substance use disorders, showing therapeutic effects.
Therapeutic effect of psilocybin in addiction: A systematic review — PMC
Psilocybin has shown promise in treating depression, with rapid-acting and enduring antidepressant effects in combination with psychological support.
📰 Source Timeline (1)
Follow how coverage of this story developed over time